Hypereosinophilic Syndrome
Hematology·MeSH: Hypereosinophilic Syndrome
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| Benralizumab | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Hypereosinophilic Syndrome?
BioSniper tracks 1 drug in development for Hypereosinophilic Syndrome across 1 company.
How many clinical trials target Hypereosinophilic Syndrome?
There are 2 clinical trials targeting Hypereosinophilic Syndrome tracked by BioSniper.
What is the prevalence of Hypereosinophilic Syndrome?
The estimated prevalence of Hypereosinophilic Syndrome is approximately 5.0 per 100,000 population.
Deep-dive into Hypereosinophilic Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis